Heng Cui

Title: Heng Cui: Innovator in Ovarian Cancer Research

Introduction

Heng Cui is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer research, particularly in the development of innovative treatments for ovarian cancer. His work focuses on the use of T-cell epitope peptides to enhance the effectiveness of cancer therapies.

Latest Patents

Heng Cui holds a patent for "T cell epitope peptides of ovarian cancer anti-idiotypic antibody 6B11 and use thereof." This invention provides two T-cell epitope peptides derived from the anti-idiotype antibody 6B11, specifically designed to target ovarian cancer cells. The sequences of these peptides are detailed in SEQ ID NO:3 or 6. The patent outlines the use of these peptides in the manufacture of vaccines aimed at treating and preventing ovarian cancer. Notably, these T-cell epitope peptides have the capability to specifically kill OC166-9 positive ovarian cancer cells, showcasing their potential in clinical applications.

Career Highlights

Heng Cui is affiliated with Peking University, where he conducts his research and development activities. His work has garnered attention for its innovative approach to cancer treatment, particularly through the use of targeted therapies that leverage the immune system.

Collaborations

Heng Cui collaborates with notable colleagues in his field, including Jie Feng and Huifang Guo. These partnerships enhance the research efforts and contribute to the advancement of cancer treatment methodologies.

Conclusion

Heng Cui's contributions to ovarian cancer research through his patented innovations highlight the importance of targeted therapies in modern medicine. His work not only advances scientific understanding but also holds promise for improving patient outcomes in the fight against cancer.